Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

BLISS GVS PHARMA LTD. - 506197 - Intimation Of GMP Compliance Certificate From TGA

 We wish to inform you that the Company has received an approval of 'Certificate of GMP Compliance of a Manufacturer' from Therapeutic Goods Administration (TGA), Department of Health, Australia for its manufacturing unit situated at Plot no. 11, Survey no. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. Dist-Palghar, 401404 after an inspection. The above information will also be available on the website of the Company at www.blissgvs.com . Kindly take the same on record and acknowledge.
18-02-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited has received request for issue of duplicate share certificates consequent to loss of share certificates from the shareholder:
11-02-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshkati' a Regional Daily, on January 31, 2022.
31-01-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2021

 We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, January 29, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matter amongst others: 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2021. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as 'Annexure - I'.
29-01-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Intimation Of Incorporation Of Step-Down Subsidiary

 With reference to the captioned subject, we would like to inform you that 'Bliss GVS International PTE Ltd' Singapore, a wholly owned subsidiary of Bliss GVS Pharma Limited ('the Company'), has incorporated a wholly owned subsidiary namely, Asterisk Lifesciences Democratic Republic of Congo ('DRC'). The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are enclosed as "Annexure - A". This is for your information and record.
28-01-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Board Meeting Intimation for Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2021

 BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2022 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from January 01, 2022 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2021. This intimation is also being uploaded on the Company''s website at http://www.blissgvs.com/. Kindly acknowledge and take on record the same.
21-01-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Shareholding for the Period Ended December 31, 2021

 Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
13-01-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Statement Of Investor Complaints For The Quarter Ended December 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 2020 Name of the Signatory :- Aditi BhattDesignation :- Company Secretary and Compliance Officer
13-01-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021 Kindly take the same on record.
11-01-2022
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that, Credit Rating of the Company has been revised by M/s. Infomerics Valuation and Rating Private Limited w.r.t. bank facilities. Please see attachment for more details.
11-01-2022
Next Page
Close

Let's Open Free Demat Account